Transcription Factor ZBP-89 Cooperates with Histone Acetyltransferase P300 During Butyrate Activation of P21waf1 Transcription in Human Cells
Overview
Authors
Affiliations
Inducible p53-independent regulation of the cyclin-dependent kinase inhibitor p21(waf1) transcription is mediated through proximal GC-rich sites. Prior studies have shown that Sp1, Sp3, and the histone acetylase co-activator p300 are components of the complexes binding to these sites. Although Sp1 and Sp3 collaborate with p300, a direct interaction between Sp1 and p300 does not occur. This study sought to determine whether ZBP-89 rather than Sp1 is the direct target of p300 during butyrate induction of p21(waf1). ZBP-89 (BFCOL1, BERF-1, ZNF 148) is a Krüppel-type zinc finger transcription factor that binds to GC-rich elements and represses or activates known target genes. Adenoviral-mediated expression of ZBP-89 in HT-29 cells revealed that ZBP-89 potentiates butyrate induction of endogenous p21(waf1) gene expression. Further, cotransfection of a ZBP-89 expression vector with a 2.3-kilobase p21(waf1) reporter recapitulated the potentiation by butyrate. DNase I footprinting analysis of the human p21(waf1) promoter with recombinant ZBP-89 identified a binding site at -245 to -215. Electrophoretic mobility shift assays confirmed that both recombinant and endogenous ZBP-89 and Sp1 bind to this element. The potentiation was abolished in the presence of adenoviral protein E1A. Deletion of the N-terminal domain of ZBP-89 abolished the potentiation mediated by butyrate treatment. This same deletion mutant abolished the ZBP-89 interaction with p300. Cotransfection of p300 with ZBP-89 stimulated the p21(waf1) promoter in the absence of butyrate. p300 co-precipitated with ZBP-89 but not with Sp1, whereas ZBP-89 co-precipitated with Sp1. Together, these findings demonstrate that ZBP-89 also plays a critical role in butyrate activation of the p21(waf1) promoter and reveals preferential cooperation of this four-zinc finger transcription factor with p300.
Angmo D, Thulkar T, Shaw E, Beri N BMJ Case Rep. 2024; 17(4).
PMID: 38642933 PMC: 11033627. DOI: 10.1136/bcr-2023-257962.
Daigle N, Duan S, Song H, Lima N, Sontz R, Merchant J J Biomed Opt. 2023; 28(9):096004.
PMID: 37711357 PMC: 10499363. DOI: 10.1117/1.JBO.28.9.096004.
Short-chain fatty acids in diseases.
Zhang D, Jian Y, Zhang Y, Li Y, Gu L, Sun H Cell Commun Signal. 2023; 21(1):212.
PMID: 37596634 PMC: 10436623. DOI: 10.1186/s12964-023-01219-9.
A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer.
Kim M, Singh M, Lee B, Hibbs M, Richardson K, Ellies L Oncogenesis. 2022; 11(1):60.
PMID: 36207293 PMC: 9546828. DOI: 10.1038/s41389-022-00435-1.
Woo A, Patry C, Ghamari A, Pregernig G, Yuan D, Zheng K Blood Adv. 2019; 3(16):2499-2511.
PMID: 31455666 PMC: 6712527. DOI: 10.1182/bloodadvances.2018030551.